Anthem Biosciences , a leading Contract Research, Development and Manufacturing Organization (CRDMO), has announced robust financial results for the first quarter, ending June 30. The company demonstrated significant growth across key financial metrics, underlining its strong market position and operational efficiency.

Financial Highlights

• Revenue Surge: Consolidated revenue from operations soared to ₹5,402.09 million, marking a substantial 59.5% increase compared to ₹3,385.94 million in the same quarter of the previous year.
• EBITDA Growth: The company reported an EBITDA of ₹2,143.00 million, up 52.7% from ₹1,404.00 million in the same quarter last year, with an EBITDA margin of 39.67%.
• Profit After Tax (PAT) Increase: PAT rose significantly to ₹1,357.91 million, representing a 64.8% growth from ₹823.79 million in the corresponding quarter. The PAT margin stood at a healthy 25.14%.
• Segment Performance:

  Segment	Revenue (₹ million)	YoY Growth
  CRDMO business	4,527.00	70.5%
  Specialty Ingredients	875.00	19.7%

Operational Highlights

• Capacity Expansion: Anthem completed the expansion of 54 kL custom synthesis capacity at Unit II (Harohalli) and commenced commercial operations.
• New Facilities: The company inaugurated state-of-the-art facilities at Unit III (NeoAnthem, Harohalli), including:
  • A dedicated commercial scale peptide manufacturing facility (16kL capacity)
  • A commercial scale hi-potent manufacturing facility (2.5kL capacity)
• Future Growth: Construction is underway for a new greenfield facility at the 30-acre site at Harohalli, Bangalore (Unit IV).

Management Commentary

Ajay Bhardwaj, Chairman, Managing Director and CEO of Anthem Biosciences, commented on the results: "We have kicked off with a strong performance, laying a solid foundation for the year ahead. Strong YoY growth reflects a CRDMO revenue stream that started ramping up since the second quarter of the previous fiscal year. A combination of a dedicated team, strategic focus, operational excellence and long-standing client partnerships has helped us deliver performance across both CRDMO and Specialty Ingredients business."

Financial Position

As of June 30, Anthem Biosciences maintained a robust net cash position of ₹7,848.00 million, indicating strong liquidity and financial stability.

Recent Developments

The company successfully completed its Initial Public Offering (IPO) with an offer for sale of 59,575,319 equity shares at an issue price of ₹570 per share. Anthem's shares were listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on July 21.

Anthem Biosciences continues to demonstrate its commitment to innovation and growth in the CRDMO sector, with its expanded facilities and strong financial performance positioning it well for future opportunities in the global pharmaceutical and biotechnology markets.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions.

Anthem Biosciences Limited , a prominent player in the biosciences sector, has announced the appointment of Ms. Divya Prasad as its Company Secretary and Compliance Officer. The appointment, which took effect on October 18, 2024, marks a significant addition to the company's leadership team.

Key Appointment Details

Ms. Prasad, who holds ICSI Membership No: A41438, brings her expertise to this crucial role within the organization. Her responsibilities include ensuring compliance with various regulatory requirements and overseeing the company's secretarial functions.

Dual Role and Responsibilities

In addition to her position as Company Secretary, Ms. Prasad will also serve as the Compliance Officer under the Securities and Exchange Board of India (SEBI) listing regulations. This dual role underscores Anthem Biosciences Limited's commitment to maintaining high standards of corporate governance and regulatory compliance.

Company Background

Anthem Biosciences Limited, formerly known as Anthem Biosciences Private Limited, is a listed entity on both major Indian stock exchanges.

Regulatory Compliance

In line with regulatory requirements, Anthem Biosciences Limited has taken steps to ensure transparency and compliance:

• The company has appointed KFin Technologies Limited as its Registrar & Share Transfer Agent, in accordance with regulation 7(1) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
• A structured digital database is maintained to record details of individuals with whom unpublished price-sensitive information is shared, as per SEBI regulations.
• The company has implemented a Code of Conduct to regulate, monitor, and report trading by its employees and other connected persons, effective from December 14, 2025.

Trading Window Closure

As part of its commitment to preventing insider trading, Anthem Biosciences Limited has announced the closure of its trading window for all Directors, Designated Persons, and other individuals covered under the company's Code of Conduct. The trading window will remain closed from July 21, 2025, until 48 hours after the declaration of financial results for the quarter ended June 30, 2025.

The appointment of Ms. Divya Prasad and the implementation of these regulatory measures reflect Anthem Biosciences Limited's dedication to maintaining high standards of corporate governance and regulatory compliance in its operations.